Back to trial detailsIntake questionnaire
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Applying to Winship Cancer Institute, Emory University · Atlanta, Georgia
Answer a few short questions to share with the research team.
0 of 4 answered